AACR· @AACR · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
The KRAS inhibitor zoldonrasib showed effective and durable responses in patients with previously treated G12D-mutated non-small cell lung cancer, according to updated results from a phase I clinical trial reported at #AACR26 by Jonathan W. Riess, MD.
https://
brnw.ch/21x1JI7
Heat 16 · 8 likes · 2 replies · 6 reposts
Source: AACR · x.com